Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 5/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.48 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.48 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.48 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1794281 | 1.00 | AOC3 (0.64) | AOC3ALDH1A1TSHRCA2CARM1 | |
| Hydrochloric Acid SCHEMBL11779718 | 0.97 | AOC3 (0.61) | AOC3ALDH1A1TSHRCA2CARM1 | |
| SCHEMBL17454767 | 0.88 | MAOB (0.60) | AOC3ALDH1A1TSHRCA2LOXL2 | |
| SCHEMBL17196392 | 0.88 | TAAR1 (0.59) | AOC3ALDH1A1TSHRCA2TAAR1 | |
| SCHEMBL16257816 | 0.85 | AOC3 (0.54) | AOC3ALDH1A1TSHRCA2CARM1 | |
| SCHEMBL1795445 | 0.85 | AOC3 (0.63) | AOC3ALDH1A1TSHRCA2CARM1 | |
| SCHEMBL1795448 | 0.85 | AOC3 (0.63) | AOC3ALDH1A1TSHRCA2CARM1 | |
| Glycine SCHEMBL3882403 | 0.84 | AOC3 (0.48) | AOC3ALDH1A1TSHRCA2CARM1 | |
| SCHEMBL17285436 | 0.83 | AOC3 (0.67) | AOC3ALDH1A1TSHRCA2CARM1 | |
| SCHEMBL2219958 | 0.82 | AOC3 (0.64) | AOC3ALDH1A1TSHRCA2CARM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 391 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024255129-A1 | RECYCLABLE EPOXY RESIN, SYSTEM MATERIAL AND COMPOSITE MATERIAL THEREOF, AND RECOVERY METHODS THEREFOR | 道生天合材料科技(上海)股份有限公司 | 2024-12-19 | — | — | WO | claimed |
| CN-118851946-A | Method for preparing long fatty chain diacid derivative and application thereof | 广东东阳光药业股份有限公司 | 2024-10-29 | — | — | CN | claimed |
| CN-118409029-A | Derivatization HPLC method for separating and measuring impurity hydrazine in carbidopa-levodopa sustained release tablet | 重庆华邦制药有限公司 | 2024-07-30 | — | — | CN | claimed |
| CN-116640415-A | Recyclable epoxy resin, system material, composite material and recycling method thereof | 道生天合材料科技(上海)股份有限公司 | 2023-08-25 | — | — | CN | claimed |
| CN-114805114-A | Preparation method of ubenimex genotoxic impurity | 上海秀新臣邦医药科技有限公司 | 2022-07-29 | — | — | CN | claimed |
| CN-111333505-B | Method for preparing long-chain fatty diacid monobenzyl ester and application thereof | 东莞市东阳光生物药研发有限公司 | 2022-07-26 | — | — | CN | claimed |
| CN-114428141-A | Method for detecting content of free hydrazine impurities in isoniazid | 北京民康百草医药科技有限公司 | 2022-05-03 | — | — | CN | claimed |
| CN-111333505-A | Method for preparing long-chain fatty diacid monobenzyl ester and application thereof | 东莞市东阳光生物药研发有限公司 | 2020-06-26 | — | — | CN | claimed |
| EP-2651420-B1 | PEPTIDE-BASED IN VIVO SIRNA DELIVERY SYSTEM | ARROWHEAD PHARMACEUTICALS INC (US) | 2018-10-03 | — | — | EP | claimed |
| EP-2651420-A2 | PEPTIDE-BASED IN VIVO SIRNA DELIVERY SYSTEM | Arrowhead Research Corporation (US) | 2013-10-23 | — | — | EP | claimed |
| US-20120165393-A1 | Peptide-Based In Vivo siRNA Delivery System | Arrowhead Madison Inc. (US) | 2012-06-28 | — | — | US | claimed |
| WO-2012083185-A2 | PEPTIDE-BASED IN VIVO SIRNA DELIVERY SYSTEM | ARROWHEAD RESEARCH CORPORATIONS (US) | 2012-06-21 | — | — | WO | claimed |
| US-20100105704-A1 | 7-(3',4'-Dialkoxyphenyl)-[1,2,4]-Triazolo[1,5-A]Pyrimidine Compounds, Process for Preparing Thereof, and Pharmaceutical Composition for Treating or Preventing Asthma, Chronic Obstructive Pulmonary Disease, Arthritis, Atopic Dermatitis, Tumor and Degenerative Brain Diseases Comprising the Same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-04-29 | — | — | US | claimed |
| WO-2008117943-A1 | 7-(3',4'-DIALKOXYPHENYL)-[1,2,4]-TRIAZOLO[1,5-A]PYRIMIDINE COMPOUNDS, PROCESS FOR PREPARING THEREOF, AND PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING ASTHMA, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ARTHRITIS, ATOPIC DERMATITIS, TUMOR AND DEGENERATIVE BRAIN DISEASES COMPRISING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-10-02 | — | — | WO | claimed |
| US-5272242-A | Hydrazino/polyhydrosilazanes | ATOCHEM (FR) | 1993-12-21 | — | — | US | claimed |
| EP-0359604-A1 | Process for preparing polyhydrosilazanes from hydrazines, and their use as precursors for ceramics | ELF ATOCHEM S.A. (FR) | 1990-03-21 | — | — | EP | claimed |
| CN-1040380-A | Preparation is by the application as the precursor of ceramic product of the method for the poly-hydrogen silazane of hydrazine derivative and described silazane | ATOCHEM (FR) | 1990-03-14 | — | — | CN | claimed |
| EP-0351262-A1 | Polysilazanes, their preparation and use as precursors for ceramic materials, and the ceramic materials | ELF ATOCHEM S.A. (FR) | 1990-01-17 | — | — | EP | claimed |
| CN-1038655-A | Polysilazane, its preparation method, and use it for ceramic precursor and make described pottery | ATOCHEM (FR) | 1990-01-10 | — | — | CN | claimed |
| EP-0327773-A1 | Polysiloxazanes, process for producing same and their use as precursors for ceramics and ceramic materials | ELF ATOCHEM S.A. (FR) | 1989-08-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105704-A1 | 7-(3',4'-Dialkoxyphenyl)-[1,2,4]-Triazolo[1,5-A]Pyrimidine Compounds, Process for Preparing Thereof, and Pharmaceutical Composition for Treating or Preventing Asthma, Chronic Obstructive Pulmonary Disease, Arthritis, Atopic Dermatitis, Tumor and Degenerative Brain Diseases Comprising the Same | TSLP, IL5, ADORA1 | AOC3 325/4885ALDH1A1 604/4885TSHR 4458/4885 |
| US-20120165393-A1 | Peptide-Based In Vivo siRNA Delivery System | VIP, RNASE1, APLNR | AOC3 4535/4885ALDH1A1 4866/4885TSHR 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.